Project Grant HT94252410345
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$2.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
The Department of the Army Medical Command awarded The Johns Hopkins University a $982,500 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting M6A Dysregulation as a Novel Therapeutic Strategy for C9ORF72-ALS". The award period is May 1, 2024 to April 30, 2026. This research aims to develop new treatments for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), with a focus on the C9ORF72 genetic...
This federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $931,500.00 to The Johns Hopkins University to develop a RIPK2 inhibitor for the treatment of ALS. The award period runs from July 1, 2025 through June 30, 2027. As a leading research university, Johns Hopkins has a strong track record of supporting critical national initiatives through cutting-edge biomedical research and scientific...
The Johns Hopkins University was awarded an $818,750 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support research into RNA-based modulation of TDP-43 mislocalization in ALS/FTD with uridine analogs from September 15, 2022 to September 14, 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This $1,137,301 federal Project Grant awarded by the Defense Health Agency on July 1, 2024 supports The Johns Hopkins University's work on "MULTI-MODAL, REMOTE TRACKING OF ALS PROGRESSION USING NOVEL DIGITAL BIOMARKERS" through June 30, 2026. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The project aims to develop...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $855,728 to The Johns Hopkins University to identify abnormally regulated lipid pathways in human motor neuron and fly models, with the goal of developing a new pharmacological drug candidate. The award period runs from Sep 1, 2024 to Aug 31, 2026. As a leading research university, Johns Hopkins has a strong track record of federal grant...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $798,272 to The Johns Hopkins University to test the use of Wnt inhibitors as a therapeutic to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The award has a performance period from March 15, 2025 to March 14, 2027 and will support advanced biomedical research focused on developing innovative medical solutions...
The Johns Hopkins University was awarded a $974,999.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, spanning August 1, 2023 to July 31, 2026, will support research to engineer an effective combination therapy of car T cells and regulatory T cells to control rejection of vascularized composite allografts. This research aims to develop medical solutions for the battlefield and transform healthcare for...
The Department of Defense's Defense Health Agency awarded a $2,058,746 Project Grant to The Johns Hopkins University to study the effects of psilocybin in patients with amyotrophic lateral sclerosis (ALS). The grant, awarded on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420), will fund this research project over a 3-year period ending on September 29, 2027. The Johns Hopkins University is a leading private research institution with extensive...
The Johns Hopkins University has been awarded a $1,099,238 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) with a period of performance from September 1, 2024 to August 31, 2026. This grant will support investigator-initiated biomedical research projects across multiple medical disciplines to improve health outcomes for military service members, veterans, and the broader public. The award enables Johns Hopkins to conduct...